NCNA NuCana plc - American Depositary Shares
NCNA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
NCNA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Financial Health Debt, liquidity, solvency — balance sheet strength
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
NCNA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
- Strong Buy 3 37.5%
- Buy 3 37.5%
- Hold 2 25.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| Sept. 30, 2024 | $-350.00 | $-545.51 | 195.5% |
| June 30, 2024 | $-600.00 | $-369.08 | -230.9% |
| March 31, 2024 | $-650.00 | $-564.79 | -85.2% |
| Dec. 31, 2023 | $-700.00 | $-522.30 | -177.7% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| NCNA | — | — | — | — | — | — |
| ROIV | $19.95B | -51.3 | -71.6% | -3629.2% | -6.5% | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 11 filers · $143K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 5 (+2 vs prior Q) | 2 (-2 vs prior Q) | 3 (+3 vs prior Q) | 0 (-2 vs prior Q) | +55K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| StoneX Group Inc. | $71,510 | 47,043 | 49.92% | Shares |
| CITADEL ADVISORS LLC | $41,190 | 27,099 | 28.75% | Shares |
| Glass Jacobson Investment Advisors llc | $22,800 | 15,000 | 15.92% | Shares |
| RHUMBLINE ADVISERS | $7,139 | 4,698 | 4.98% | Shares |
| Integrated Wealth Concepts LLC | $286 | 188 | 0.20% | Shares |
| CITIGROUP INC | $286 | 188 | 0.20% | Shares |
| HRT FINANCIAL LP | $25 | 16,870 | 0.02% | Shares |
| Caitong International Asset Management Co., Ltd | $8 | 5 | 0.01% | Shares |
| MORGAN STANLEY | $3 | 2 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $2 | 1 | 0.00% | Shares |
| ACADIAN ASSET MANAGEMENT LLC | $0 | 2 | 0.00% | Shares |
Company insiders 3 insiders · 2 officers · 1 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Theresa Margaret Ms Bruce | Chief Operating Officer | April 15, 2026 A | — | 0 | 0 | $0 |
| Jeffrey D. Bloss | Chief Medical Officer | June 19, 2026 D | — | 0 | 0 | $0 |
| Elliott M. Levy | Director | June 19, 2026 D | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
Activists & 5%+ owners 6 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Hugh S. Griffith | March 18, 2026 | 12.00% | Initial filing | Passive investment | SEC |
| Sofinnova Venture Partners VIII, L.P., Sofinnova Management VIII, L.L.C., Sofinnova Venture Partners X, L.P., Sofinnova Management X, L.P., Sofinnova Management X-A, L.L.C., Dr. James I. Healy, Dr. Maha Katabi | Feb. 25, 2025 | 0.10% | Amendment | Passive investment | SEC |
| Sofinnova Capital VI FCPR, Sofinnova Partners SAS, Antoine Papiernik, Henrijette Richter, Maina Bhaman, Graziano Seghezzi, Anta Gkelou, Karl Naegler | Feb. 14, 2025 | 5.10% | Amendment | Passive investment | SEC |
| Sofinnova Venture Partners VIII, L.P. (“SVP VIII”), Sofinnova Management VIII, L.L.C. (“SM VIII”), Dr. James I. Healy (“Healy”), Dr. Maha Katabi (“Katabi”), Sofinnova Venture Partners X, L.P. (“SVP X”), Sofinnova Management X, L.P. (“SM X LP”), Sofinnova Management X- A , L.L.C. (“SM X LLC”) ×4 filings | Feb. 27, 2024 | — | Initial filing | Passive investment | SEC |
| Sofinnova Capital VI FCPR (“SC VI”), Sofinnova Partners SAS, a French corporation (“SP SAS”), Denis Lucquin (“Lucquin”), Antoine Papiernik (“Papiernik”), Henrijette Richter (“Richter”), Monique Saulnier (“Saulnier”), Graziano Seghezzi (“Seghezzi”) ×6 filings | June 15, 2021 | — | Initial filing | — | SEC |
| Abingworth LLP, Abingworth Bioventures VII, LP | Sept. 28, 2020 | — | Initial filing | Board campaign | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.